Similar articles

• Cholesterol reduction, statins and the cytochrome P-450 system. No more recipes please.

  Bortolini M. Bortolini M. Eur Heart J. 2001 Aug;22(16):1514-6. doi: 10.1053/euhj.2000.2524. Eur Heart J. 2001. PMID: 11482929 No abstract available.
• Update: clinically significant cytochrome P-450 drug interactions.

  Michalets EL. Michalets EL. Pharmacotherapy. 1998 Jan-Feb;18(1):84-112. Pharmacotherapy. 1998. PMID: 9469685 Review.
• Drug-drug interactions: how scared should we be?

  Shapiro LE, Shear NH. Shapiro LE, et al. CMAJ. 1999 Nov 16;161(10):1266-7. CMAJ. 1999. PMID: 10584089 Free PMC article. No abstract available.
• Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.

  Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Baner K, Benet LZ, Sewing KF, Christians U. Jacobsen W, et al. J Pharmacol Exp Ther. 1999 Oct;291(1):131-9. J Pharmacol Exp Ther. 1999. PMID: 10490896
• The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine.

  Davis MP, Homsi J. Davis MP, et al. Support Care Cancer. 2001 Sep;9(6):442-51. doi: 10.1007/s005200000222. Support Care Cancer. 2001. PMID: 11585271 Review.